Pharmacology Fundamentals for Nursing Practice

Overview

Pharmacology is the scientific study of drugs and their interactions with living systems. For the BSN-prepared nurse, pharmacological knowledge is not merely academic — it is an essential clinical competency that underpins every aspect of safe, effective medication management. The nurse is the last defense before a medication reaches the patient, making pharmacological literacy a patient safety imperative.

This reference entry covers the foundational science of how drugs move through the body (pharmacokinetics) and how they produce effects (pharmacodynamics), the mathematical principles that underpin safe dosing, the major drug classes encountered across clinical settings, and the guidelines that govern safe practice. Taken together, these concepts form the pharmacological knowledge base expected of every entry-level BSN nurse.

---

Pharmacokinetics: What the Body Does to the Drug

Pharmacokinetics (PK) describes the journey of a drug through the body across four interdependent processes, often abbreviated ADME: Absorption, Distribution, Metabolism, and Excretion. Understanding PK explains why doses differ across routes and populations, why some drugs require loading doses, and why organ impairment demands dose adjustment.

Absorption

Absorption is the process by which a drug moves from its site of administration into the systemic circulation. The rate and extent of absorption determine how quickly a drug begins to act and how much of the administered dose reaches the bloodstream.

Key factors influencing absorption include:

• Route of administration — Intravenous (IV) administration delivers drug directly into circulation (100% bioavailability by definition); oral drugs must survive the gastrointestinal environment and first-pass hepatic metabolism before reaching the systemic circulation.
• Bioavailability (F) — The fraction of an administered dose that reaches systemic circulation unchanged. Oral bioavailability is always less than 1.0 (e.g., morphine oral bioavailability ≈ 0.25, meaning 75% is lost to first-pass metabolism).
• First-pass effect — Orally absorbed drugs pass through the portal circulation to the liver before reaching systemic circulation; hepatic enzymes may substantially reduce the active drug concentration. This is why some drugs (e.g., nitroglycerin, lidocaine) cannot be given orally or require much higher oral doses than IV doses.
• GI factors — Gastric pH, gut motility, the presence of food, and mucosal surface area all influence absorption of oral medications. Enteric-coated and sustained-release formulations are engineered to control absorption timing.

Distribution

Distribution is the movement of an absorbed drug from the systemic circulation to tissues and organs. The extent of distribution is described by the volume of distribution (Vd) — a theoretical value representing how widely a drug is dispersed throughout body compartments.

Important distribution concepts:

• Plasma protein binding — Many drugs bind reversibly to plasma proteins (primarily albumin). Only the free (unbound) fraction is pharmacologically active. Patients with hypoalbuminemia (e.g., malnutrition, liver disease, nephrotic syndrome) have increased free drug fractions and are at risk of enhanced effects or toxicity at standard doses.
• Blood-brain barrier (BBB) — Lipid-soluble drugs cross the BBB more readily than polar, highly protein-bound drugs. This determines which CNS-active drugs achieve therapeutic brain concentrations.
• Lipophilicity — Lipid-soluble drugs distribute widely into adipose tissue, creating large Vd values and prolonged duration of action. Obese patients may require dose adjustments for highly lipophilic drugs.

Metabolism (Biotransformation)

Metabolism is the enzymatic transformation of drugs, primarily in the liver, into metabolites that are typically more water-soluble and more easily excreted. The cytochrome P450 (CYP) enzyme system — particularly CYP3A4, CYP2D6, and CYP2C9 — mediates the metabolism of the majority of clinical drugs.

Clinically important metabolism concepts:

• Prodrugs — Some drugs are administered in an inactive form and require hepatic metabolism to become active (e.g., codeine → morphine via CYP2D6; clopidogrel → active thienopyridine via CYP2C19). Genetic polymorphisms or drug interactions affecting these enzymes can dramatically alter drug efficacy.
• Enzyme induction vs. inhibition — Drug interactions frequently occur at the CYP enzyme level. Enzyme inducers (e.g., rifampin, phenytoin, St. John’s Wort) increase metabolism and reduce plasma drug levels; enzyme inhibitors (e.g., fluconazole, erythromycin, grapefruit juice) decrease metabolism and increase plasma levels, risking toxicity.
• Hepatic impairment — Patients with cirrhosis or severe hepatic dysfunction have reduced first-pass metabolism and decreased protein synthesis (affecting protein binding). Dose reductions are often required.

Excretion

Excretion is the removal of drugs and their metabolites from the body, predominantly via the kidneys (renal excretion) and, to a lesser extent, bile, feces, lungs, and sweat.

• Renal clearance — Glomerular filtration, tubular secretion, and tubular reabsorption all influence how much drug is eliminated by the kidneys. The glomerular filtration rate (GFR) or creatinine clearance (CrCl) is used to adjust doses of renally cleared drugs. As renal function declines, drug and metabolite accumulation leads to toxicity.
• Half-life (t½) — The time required for the plasma concentration of a drug to decrease by 50%. After approximately five half-lives, a drug is essentially eliminated from the body. Drugs with long half-lives (e.g., amiodarone t½ ≈ 40–55 days) require extended monitoring after discontinuation.
• Steady state — With repeated dosing, a drug accumulates until the rate of administration equals the rate of elimination. Steady state is reached after approximately five half-lives.

---

Pharmacodynamics: What the Drug Does to the Body

Pharmacodynamics (PD) describes the mechanisms by which drugs produce their biological effects, including the relationship between drug concentration and response.

Receptor Theory

Most drugs exert their effects by binding to specific receptor proteins on cell surfaces, inside cells, or on ion channels. The binding triggers a conformational change in the receptor that initiates a downstream signaling cascade.

Receptor Interaction	Definition	Clinical Example
Agonist	Binds to receptor and activates it, producing an effect	Morphine at μ-opioid receptors → analgesia
Antagonist	Binds to receptor and blocks it without activating; prevents agonist binding	Naloxone at μ-opioid receptors → reversal of opioid effects
Partial agonist	Binds and activates receptor, but with submaximal efficacy even at full occupancy	Buprenorphine at μ-opioid receptors
Inverse agonist	Binds receptor and produces the opposite effect of the endogenous agonist	Certain antihistamines

Dose-Response Relationships

The dose-response curve (DRC) describes the relationship between drug concentration and the magnitude of drug effect. Key parameters include:

• Efficacy — The maximum effect a drug can produce (represented by the ceiling or plateau of the DRC). A drug with high efficacy produces a greater maximum response than one with low efficacy.
• Potency — The dose required to produce 50% of the maximum effect (ED₅₀). A more potent drug achieves the same effect at a lower dose compared to a less potent drug.
• Therapeutic index (TI) — The ratio of the dose that produces toxicity in 50% of subjects (TD₅₀) to the dose that produces the desired effect in 50% of subjects (ED₅₀). Drugs with a narrow therapeutic index (e.g., digoxin, warfarin, lithium, aminoglycosides, phenytoin) require close monitoring because the margin between therapeutic and toxic concentrations is small.

---

Drug Math: Principles and Calculations

Safe medication administration requires proficiency in drug dosage calculations. Errors in drug math are a leading cause of preventable medication errors; the nurse must be able to perform these calculations accurately and verify automated systems independently.

Dimensional Analysis (Factor-Label Method)

Dimensional analysis is the preferred method for drug calculations because it is systematic, self-checking, and reduces error. The method involves setting up a series of equivalent fractions (conversion factors) that cancel unwanted units, leaving only the desired unit.

General framework:

Desired unit = Given quantity × (Conversion factor 1) × (Conversion factor 2) ...

Example 1 — Oral dose calculation:

Ordered: Metoprolol 37.5 mg PO. Available: Metoprolol 25 mg tablets.

tablets = 37.5 mg × (1 tablet / 25 mg) = 1.5 tablets

Example 2 — IV infusion rate:

Ordered: Heparin 1,200 units/hour IV. Available: Heparin 25,000 units in 500 mL NS.

mL/hour = 1,200 units/hour × (500 mL / 25,000 units) = 24 mL/hour

Example 3 — Weight-based dosing:

Ordered: Dopamine 5 mcg/kg/min. Patient weight: 80 kg. Available: Dopamine 400 mg in 250 mL D5W.

Step 1: Convert mg to mcg — 400 mg × 1,000 mcg/mg = 400,000 mcg in 250 mL.

Concentration = 400,000 mcg / 250 mL = 1,600 mcg/mL.

Step 2: Calculate dose in mcg/min — 5 mcg/kg/min × 80 kg = 400 mcg/min.

Step 3: Convert to mL/hour — 400 mcg/min × (60 min/1 hour) × (1 mL / 1,600 mcg) = 15 mL/hour.

IV Drip Rate Calculations

For gravity infusions (where electronic pumps are unavailable), the nurse must calculate drops per minute:

Drops/min = (Volume to infuse in mL × Drop factor) / Time in minutes

Common drop factors: 10, 15, 20 gtt/mL (macrodrip) and 60 gtt/mL (microdrip/pediatric).

Example: Infuse 1,000 mL NS over 8 hours via a 15 gtt/mL macrodrip set.

Drops/min = (1,000 mL × 15 gtt/mL) / (8 hours × 60 min/hour) = 15,000 / 480 ≈ 31 gtt/min

Pediatric Dosing

Pediatric dosing is typically weight-based (mg/kg). Always verify:

1. Calculate dose in mg/kg and confirm it falls within the recommended range
2. Calculate the volume to administer from the available concentration
3. Confirm the dose with a second nurse for high-alert medications

Example: Amoxicillin 40 mg/kg/day PO divided every 8 hours. Patient weight: 15 kg. Available: 250 mg/5 mL suspension.

Daily dose = 40 mg/kg × 15 kg = 600 mg/day. Per dose = 600 mg / 3 doses = 200 mg per dose.

Volume per dose = 200 mg × (5 mL / 250 mg) = 4 mL per dose.

---

Major Drug Classes: Nursing Considerations

The following table summarizes the major drug classes encountered across clinical nursing settings. For detailed monographs on individual agents, see the Pharmacology reference collection.

Cardiovascular Agents

Drug Class	Mechanism	Key Examples	Key Nursing Considerations
ACE Inhibitors	Block angiotensin-converting enzyme → reduce angiotensin II → vasodilation + reduced aldosterone	Lisinopril, enalapril, captopril	Monitor BP; hold for SBP < 90 mmHg; monitor K⁺ and creatinine; teach to report dry cough (class effect); avoid in pregnancy
ARBs	Block angiotensin II AT₁ receptors → vasodilation	Losartan, valsartan	Same as ACEi without cough; avoid in pregnancy; monitor K⁺ and renal function
Beta-Blockers	Block β-adrenergic receptors → reduce HR, contractility, BP	Metoprolol, carvedilol, atenolol	Hold for HR < 60 bpm; never abruptly discontinue; monitor for bronchospasm in asthma/COPD
Calcium Channel Blockers	Block L-type Ca²⁺ channels → vasodilation ± reduced HR/contractility	Amlodipine, diltiazem, verapamil	Monitor BP and HR; diltiazem/verapamil → bradycardia; do not crush extended-release
Nitrates	Release NO → venodilation → reduced preload	Nitroglycerin, isosorbide	Hold for SBP < 90 mmHg; monitor for headache; 8-hour nitrate-free period to prevent tolerance; contraindicated with PDE-5 inhibitors
Statins	Inhibit HMG-CoA reductase → reduce cholesterol synthesis	Atorvastatin, rosuvastatin, simvastatin	Monitor LFTs and CPK; report muscle pain/weakness (myopathy/rhabdomyolysis); avoid grapefruit with some statins
Anticoagulants — Heparin	Potentiates antithrombin III → inhibits thrombin and Xa	Heparin, enoxaparin	Monitor aPTT (UFH) or anti-Xa (LMWH); antidote = protamine sulfate; assess for bleeding
Anticoagulants — Direct Oral	Direct thrombin (dabigatran) or Xa inhibition (rivaroxaban, apixaban)	Rivaroxaban, apixaban, dabigatran	No routine coagulation monitoring; assess for bleeding; reversal agents available (andexanet alfa for Xa; idarucizumab for dabigatran)
Warfarin	Inhibits vitamin K–dependent clotting factors (II, VII, IX, X)	Warfarin	Monitor INR; target INR 2–3 (most indications); many drug/food interactions; antidote = vitamin K, FFP

Respiratory Agents

Drug Class	Mechanism	Key Examples	Key Nursing Considerations
Short-Acting Beta₂ Agonists (SABAs)	β₂ receptor activation → bronchodilation	Albuterol, levalbuterol	Use for acute bronchospasm rescue; teach correct inhaler technique; monitor HR
Inhaled Corticosteroids (ICS)	Reduce airway inflammation	Budesonide, fluticasone, beclomethasone	Rinse mouth after use to prevent oral candidiasis; for maintenance, not rescue
Anticholinergics	Block muscarinic receptors → bronchodilation + reduced secretions	Ipratropium, tiotropium	Use with caution in BPH and narrow-angle glaucoma; avoid contact with eyes

Endocrine Agents

Drug Class	Mechanism	Key Examples	Key Nursing Considerations
Insulin	Facilitates cellular glucose uptake; inhibits glycogenolysis	All insulin types	HIGH ALERT — independent double-check required; verify type, dose, and patient; monitor blood glucose; rotate sites
Oral Antidiabetics — Metformin	Reduces hepatic glucose production; improves insulin sensitivity	Metformin	Hold 48 hours before/after iodinated contrast; withhold for renal impairment (eGFR < 30); does not cause hypoglycemia alone
Sulfonylureas	Stimulate pancreatic insulin release	Glipizide, glyburide	Risk of hypoglycemia; administer with food; elderly at highest risk
GLP-1 Receptor Agonists	Enhance glucose-dependent insulin secretion; reduce appetite	Semaglutide, liraglutide	GI side effects common; assess for pancreatitis; may cause weight loss
Thyroid — Levothyroxine	Synthetic T4 for hypothyroidism	Levothyroxine	Take on empty stomach 30–60 min before food; monitor TSH; many drug interactions affect absorption

Analgesic Agents

Drug Class	Mechanism	Key Examples	Key Nursing Considerations
Opioids	μ-opioid receptor agonism → analgesia + CNS depression	Morphine, oxycodone, fentanyl, hydromorphone	HIGH ALERT; assess pain, respiratory rate, sedation; naloxone at bedside; constipation prophylaxis; monitor for tolerance and dependence
NSAIDs	Inhibit COX-1 and COX-2 → reduce prostaglandins	Ibuprofen, naproxen, ketorolac	Avoid in renal impairment, peptic ulcer disease, third-trimester pregnancy; administer with food; monitor for GI bleeding
Acetaminophen	Central COX inhibition; exact mechanism unclear	Acetaminophen (Tylenol)	Maximum adult dose 4 g/day (2 g/day for chronic alcohol use or liver disease); monitor for hepatotoxicity; check all combination products for hidden acetaminophen

Anti-Infective Agents

Drug Class	Mechanism	Key Examples	Key Nursing Considerations
Penicillins	Inhibit cell wall synthesis	Amoxicillin, ampicillin, nafcillin	Ask about PCN allergy before administration; cross-reactivity with cephalosporins (~1–2%); administer doses evenly spaced
Cephalosporins	Inhibit cell wall synthesis	Cefazolin, ceftriaxone, cefepime	Ask about PCN/cephalosporin allergy; broad-spectrum coverage improves with each generation
Fluoroquinolones	Inhibit bacterial DNA gyrase and topoisomerase IV	Ciprofloxacin, levofloxacin	Risk of tendon rupture (especially Achilles); avoid in children and pregnant patients; QTc prolongation risk
Vancomycin	Inhibits cell wall synthesis by binding D-Ala–D-Ala	Vancomycin	Monitor trough levels (or AUC/MIC); “Red Man Syndrome” with rapid infusion — infuse over ≥60 minutes; monitor renal function
Aminoglycosides	Inhibit 30S ribosomal subunit → protein synthesis disruption	Gentamicin, tobramycin	Narrow therapeutic index; nephrotoxic and ototoxic; monitor peaks, troughs, and renal function

Neurological and Psychiatric Agents

Drug Class	Mechanism	Key Examples	Key Nursing Considerations
SSRIs	Inhibit serotonin reuptake	Sertraline, fluoxetine, escitalopram	2–6 weeks for full effect; monitor for serotonin syndrome; increased suicidality risk in young patients initially — monitor closely
Antiepileptics	Various CNS stabilizing mechanisms	Phenytoin, valproate, levetiracetam	Monitor drug levels for narrow-TI agents; teratogenic risk; do not abruptly discontinue
Benzodiazepines	GABA-A receptor potentiation → CNS depression	Lorazepam, diazepam, midazolam	Risk of respiratory depression; fall risk; dependence with long-term use; flumazenil reversal for respiratory depression

---

Safe Medication Administration: Guidelines and Checklists

The Six Rights of Medication Administration

Every medication administration event must begin with systematic verification of the six rights. These checks are non-negotiable and represent the minimum standard of safe practice.

Right	Verification Action
Right Patient	Confirm two unique identifiers (name + DOB or name + MRN); scan barcode at bedside if BCMA available
Right Medication	Match drug name on label against the MAR; verify both generic and brand names; never rely on label appearance alone
Right Dose	Calculate and verify the dose; for high-alert medications, have a second nurse independently verify
Right Route	Confirm the ordered route is appropriate and feasible; never assume route without verification
Right Time	Administer within the accepted window (typically ±30 minutes for scheduled medications)
Right Documentation	Document administration after giving the medication, not before

Pre-Administration Safety Checklist

Before administering any medication, the nurse should verify:

• Patient allergies reviewed and medication cleared
• Relevant vital signs assessed and within acceptable parameters for that drug
• Relevant laboratory values reviewed (e.g., INR, K⁺, renal function, blood glucose)
• Drug interactions screened
• Indication confirmed — is this medication still clinically appropriate?
• Patient education provided — patient understands the medication’s purpose and expected effects

Common Drug Interaction Patterns

Nurses are not expected to memorize every drug interaction, but should recognize the most dangerous patterns and know how to access drug interaction databases:

• QTc-prolonging combinations — Combining multiple QTc-prolonging drugs (e.g., azithromycin + haloperidol + ondansetron) can precipitate torsades de pointes; ECG monitoring and provider notification are warranted
• CNS depressant combinations — Opioids + benzodiazepines + antihistamines + alcohol = additive respiratory depression; avoid concurrent use unless clearly indicated and monitored
• Warfarin interactions — Dozens of drugs and foods affect INR; always check after starting or stopping any medication in a warfarin-anticoagulated patient
• Nephrotoxic combinations — NSAIDs + ACE inhibitors + aminoglycosides in a dehydrated patient = high risk of acute kidney injury

Recognizing and Responding to Adverse Drug Reactions

Reaction Type	Presentation	Immediate Action
Anaphylaxis	Urticaria, angioedema, bronchospasm, hypotension within minutes of exposure	Stop drug; call rapid response/code; epinephrine 0.3 mg IM vastus lateralis; position supine with legs elevated; maintain airway
Opioid toxicity	Respiratory rate < 8/min, miosis, decreased consciousness, bradycardia	Stimulate patient; administer naloxone 0.4–2 mg IV/IM/intranasal; prepare to support ventilation
Digoxin toxicity	Bradycardia, AV block, visual changes (yellow-green halos), nausea/vomiting	Hold digoxin; obtain digoxin level; monitor ECG; provider notification; Digibind if severe
Serotonin syndrome	Agitation, tremor, myoclonus, hyperthermia, tachycardia after adding serotonergic agent	Discontinue offending agents; notify provider; cyproheptadine (antihistamine) may be used; supportive care
Neuroleptic malignant syndrome	Hyperthermia, “lead-pipe” rigidity, altered consciousness with antipsychotic use	Discontinue antipsychotic; emergency supportive care; dantrolene

---

Key Terminology Glossary

Term	Definition
Bioavailability	Fraction of an administered dose that reaches systemic circulation unchanged
Clearance	The rate at which a drug is eliminated from the plasma (mL/min)
Drug tolerance	Decreased drug response with repeated exposure, requiring higher doses for the same effect
Efficacy	The maximum effect a drug can produce
Half-life (t½)	Time for plasma drug concentration to decrease by 50%
Pharmacogenomics	The study of how genetic variation affects individual drug response
Polypharmacy	The concurrent use of multiple medications; risk factor for adverse drug reactions and interactions
Potency	The dose required to produce 50% of the maximum effect (ED₅₀)
Prodrug	An inactive drug that is metabolized to its active form in the body
Steady state	Plasma drug concentration reached when the rate of drug administration equals the rate of elimination (achieved after ~5 half-lives)
Therapeutic index	Ratio of the toxic dose to the effective dose; narrow TI drugs require close monitoring

---

References

• Lehne, R. A., & Rosenthal, L. D. (2022). Pharmacology for nursing care (11th ed.). Elsevier.
• Institute for Safe Medication Practices (ISMP). (2023). ISMP list of high-alert medications in acute care settings. https://www.ismp.org
• Katzung, B. G. (Ed.). (2021). Basic and clinical pharmacology (15th ed.). McGraw-Hill.
• American Association of Colleges of Nursing (AACN). (2021). The essentials: Core competencies for professional nursing education. https://www.aacnnursing.org
• NCSBN. (2023). Next generation NCLEX (NGN) test plan. https://www.ncsbn.org